Patent · US Active

Use of cyclolignans and new cyclolignans

US7709526B2 · kind B2 · utility

4Cited by

2References

10Claims

0Family size

Assignee

Biovitrum AB · SE

Inventors

Olle Larsson · Kronach, DE
Magnus Axelson · Hässelby, SE

Key dates

Filing date	Feb 3, 2006
Grant date	May 4, 2010
Priority date	—
Expiry date	Sep 28, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D317/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF-1 R dependent diseases, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.